Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-28

Clinical Trial Update: CP-751,871 Treatment For Patients With Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial of CP-751,871 in patients with multiple myeloma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CP-751,871 (dalotuzumab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2013-02-28